Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial
- PMID: 24849105
- DOI: 10.1093/eurheartj/ehu213
Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial
Abstract
Aims: Coronary artery bypass grafting (CABG) has been considered the standard of care for patients with three-vessel disease (3VD), but long-term comparative results from randomized trials of CABG vs. percutaneous coronary intervention (PCI) using drug-eluting stents (DES) remain limited.
Methods and results: Patients with de novo 3VD or left main disease were randomly assigned to PCI with the paclitaxel-eluting first-generation stent or CABG in the SYNTAX trial. This pre-specified analysis presents the 5-year outcomes of patients with 3VD (n = 1095). The rate of major adverse cardiac and cerebrovascular events (MACCE) was significantly higher in patients with PCI compared with CABG (37.5 vs. 24.2%, respectively; P < 0.001). Percutaneous coronary intervention as opposed to CABG resulted in significantly higher rates of the composite of death/stroke/myocardial infarction (MI) (22.0 vs. 14.0%, respectively; P < 0.001), all-cause death (14.6 vs. 9.2%, respectively; P = 0.006), MI (9.2 vs. 4.0%, respectively; P = 0.001), and repeat revascularization (25.4 vs. 12.6%, respectively; P < 0.001); however, stroke was similar between groups at 5 years (3.0 vs. 3.5%, respectively; P = 0.66). Results were dependent on lesion complexity (P for interaction = 0.12); in patients with a low (0-22) SYNTAX score, PCI vs. CABG resulted in similar rates of MACCE (33.3% vs. 26.8%, respectively; P = 0.21) but significantly more repeat revascularization (25.4% vs. 12.6%, respectively; P = 0.038), while in intermediate (23-32) or high (≥ 33) SYNTAX score terciles, CABG demonstrated clear superiority in terms of MACCE, death, MI, and repeat revascularization. Differences in MACCE between PCI and CABG were larger in diabetics [hazard ratio (HR) = 2.30] than non-diabetics (HR = 1.51), although the P for interaction failed to reach significance for MACCE (P for interaction = 0.095) or any of the other endpoints.
Conclusion: Five-year results of patients with 3VD treated with CABG or PCI using the first-generation paclitaxel-eluting DES suggest that CABG should remain the standard of care as it resulted in significantly lower rates of death, MI, and repeat revascularization, while stroke rates were similar. For patients with low SYNTAX scores, PCI is an acceptable revascularization strategy, although at a price of significantly higher rates of repeat revascularization.
Clinical trial registration: NCT00114972.
Keywords: Coronary artery bypass grafting; Diabetes; Incomplete revascularization; Percutaneous coronary intervention; Randomized trial; SYNTAX; Three-vessel disease.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com.
Comment in
-
Coronary artery disease: Long-term superiority of CABG surgery for three-vessel disease confirmed.Nat Rev Cardiol. 2014 Jul;11(7):372. doi: 10.1038/nrcardio.2014.82. Epub 2014 Jun 10. Nat Rev Cardiol. 2014. PMID: 24913059 No abstract available.
-
Percutaneous or surgical revascularization in multivessel coronary artery disease: synthesis from SYNTAX.Eur Heart J. 2014 Oct 21;35(40):2789-91. doi: 10.1093/eurheartj/ehu253. Epub 2014 Jun 26. Eur Heart J. 2014. PMID: 24970337 No abstract available.
Similar articles
-
Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial.Eur J Cardiothorac Surg. 2013 May;43(5):1006-13. doi: 10.1093/ejcts/ezt017. Epub 2013 Feb 14. Eur J Cardiothorac Surg. 2013. PMID: 23413014 Clinical Trial.
-
Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial.Circulation. 2014 Jun 10;129(23):2388-94. doi: 10.1161/CIRCULATIONAHA.113.006689. Epub 2014 Apr 3. Circulation. 2014. PMID: 24700706 Clinical Trial.
-
Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.Circulation. 2014 Sep 30;130(14):1146-57. doi: 10.1161/CIRCULATIONAHA.114.009985. Epub 2014 Aug 1. Circulation. 2014. PMID: 25085960 Clinical Trial.
-
Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients.Am Heart J. 2017 Aug;190:54-63. doi: 10.1016/j.ahj.2017.05.005. Epub 2017 May 18. Am Heart J. 2017. PMID: 28760214 Review.
-
Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.J Am Coll Cardiol. 2018 Jul 24;72(4):386-398. doi: 10.1016/j.jacc.2018.04.071. J Am Coll Cardiol. 2018. PMID: 30025574
Cited by
-
Left Internal Mammary Artery Versus Coronary Stents: Impact on Downstream Coronary Stenoses and Conduit Patency.J Am Heart Assoc. 2016 Sep 24;5(9):e003568. doi: 10.1161/JAHA.116.003568. J Am Heart Assoc. 2016. PMID: 27664803 Free PMC article.
-
Prediction of 1-year clinical outcomes using the SYNTAX score in patients with prior heart failure undergoing percutaneous coronary intervention: sub-analysis of the SHINANO registry.Heart Vessels. 2017 Apr;32(4):399-407. doi: 10.1007/s00380-016-0896-9. Epub 2016 Oct 5. Heart Vessels. 2017. PMID: 27709325 Free PMC article.
-
Minimally invasive surgery or stenting for left anterior descending artery disease - meta-analysis.Int J Cardiol Heart Vasc. 2022 May 10;40:101046. doi: 10.1016/j.ijcha.2022.101046. eCollection 2022 Jun. Int J Cardiol Heart Vasc. 2022. PMID: 35573649 Free PMC article. Review.
-
The magnitude of the survival benefit of internal thoracic artery grafting: Absolute risk reduction.JTCVS Open. 2021 Nov 20;9:106-111. doi: 10.1016/j.xjon.2021.11.008. eCollection 2022 Mar. JTCVS Open. 2021. PMID: 36003479 Free PMC article.
-
Minimally Invasive Isolated and Hybrid Surgical Revascularization for Multivessel Coronary Disease: A Single-Center Long-Term Follow-Up.J Pers Med. 2024 May 15;14(5):528. doi: 10.3390/jpm14050528. J Pers Med. 2024. PMID: 38793110 Free PMC article.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous